July, 2024
July 2024
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
293031  
Results from the NIAGARA Phase III trial
Jun 26, 2024, 15:22

Results from the NIAGARA Phase III trial

AztraZeneca released the results of the NIAGARA phase III trial, where INFINZI (durvalumab) showed EFS and OS for MIBC.

Thomas Powles, Director of Barts Cancer Centre, one of the investigators, shared his thoughts:

“Positive results from the NIAGARA Phase III trial showed durvalumab with neoadjuvant chemo then cystectomy had a statistically significant and clinically meaningful improvement in EFS and OS benefit versus chemo/cystectomy alone in muscle-invasive bladder cancer.”

NIAGARA

Here are some comments from oncologists on this announcement on X:

Jason Brown:

“Perioperative durvalumab with EFS and OS benefit in MIBC. Great news for our patients and look forward to seeing the data.”

Enrique Grande:

“Great news for muscle-invasive bladder cancer patients! Durvalumab demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial.”

Laura Bukavina:

“Addition of durvalumab to NAC before Cystectomy and continuation after Cystectomy (adjuvant) with increased EFS and increased OS.”

“Looking forward to data particularly in CR or ctDNA negative patients.. what’s the benefit of additional adjuvant durvalumab.”

Toni Choueiri:

“Just in: Durvalumab extends EFS and OS. In muscle-invasive bladder cancer —major news with IO moving earlier stages in bladder cancer!”

NIAGARA

Yüksel Ürün:

“Evidence for the efficacy of neoadjuvant immunotherapy is increasing. The ideal place is not yet clear.”

Paolo Tarantino:

“Neoadjuvant chemo/IO taking over across oncology fields. Contribution of neoadjuvant vs. adjuvant IO remains mostly unknown, though.”

Read the official announcement and further details on this study.